Roche, Promega Settle Long-Standing PCR Patent Battle
The terms of the agreement have not been released.
Roche sued Promega in 1992, asserting two patents for its DNA-replication process known as “polymerase chain reaction” (PCR), and one patent for a ground-breaking enzyme important to the PCR process called “Taq”.
The Roche complaint addressed the terms of Promega’s Taq-related license from biotechnology firm Ceta Corporation, which Roche had...
To view the full article, register now.